New drug aims to tame chemo side effects in bladder cancer patients

NCT ID NCT07484022

First seen Mar 20, 2026 · Last updated May 21, 2026 · Updated 9 times

Summary

This early-phase study tests an investigational drug called GB-4362 in 37 adults with advanced bladder cancer who are already receiving standard treatments. The drug is designed to neutralize a chemotherapy byproduct that can cause nerve damage and other side effects. The main goal is to see if adding GB-4362 is safe and tolerable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MSK

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Midwestern Regional Medical Center

    RECRUITING

    Zion, Illinois, 60099, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Orlando Health

    RECRUITING

    Orlando, Florida, 32806, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Southeastern Regional Medical Center

    RECRUITING

    Tucker, Georgia, 30084, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Start New York, LLC

    RECRUITING

    Lake Success, New York, 11042, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.